GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » ROA %

Karuna Therapeutics (Karuna Therapeutics) ROA % : -33.46% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Karuna Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-455.30 Mil. Karuna Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $1,360.65 Mil. Therefore, Karuna Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -33.46%.

The historical rank and industry rank for Karuna Therapeutics's ROA % or its related term are showing as below:

KRTX' s ROA % Range Over the Past 10 Years
Min: -283.33   Med: -32.86   Max: -18.51
Current: -31.55

During the past 7 years, Karuna Therapeutics's highest ROA % was -18.51%. The lowest was -283.33%. And the median was -32.86%.

KRTX's ROA % is not ranked
in the Biotechnology industry.
Industry Median: -34.99 vs KRTX: -31.55

Karuna Therapeutics ROA % Historical Data

The historical data trend for Karuna Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karuna Therapeutics ROA % Chart

Karuna Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial -21.50 -18.51 -32.86 -32.68 -34.70

Karuna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.49 -29.13 -27.62 -33.35 -33.46

Competitive Comparison of Karuna Therapeutics's ROA %

For the Biotechnology subindustry, Karuna Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karuna Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karuna Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Karuna Therapeutics's ROA % falls into.



Karuna Therapeutics ROA % Calculation

Karuna Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-433.68/( (1163.334+1336.209)/ 2 )
=-433.68/1249.7715
=-34.70 %

Karuna Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-455.296/( (1385.097+1336.209)/ 2 )
=-455.296/1360.653
=-33.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Karuna Therapeutics  (NAS:KRTX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-455.296/1360.653
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-455.296 / 0)*(0 / 1360.653)
=Net Margin %*Asset Turnover
=N/A %*0
=-33.46 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Karuna Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Karuna Therapeutics (Karuna Therapeutics) Business Description

Traded in Other Exchanges
Address
99 High Street, 26th Floor, Boston, MA, USA, 02110
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
Executives
Stephen K. Brannan officer: Chief Medical Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown officer: Chief Financial Officer KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller officer: Chief Operating Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr officer: Chief Commercial Officer C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury director, officer: President and CEO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins officer: Chief Commercial Officer C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul director, officer: President & CEO C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045

Karuna Therapeutics (Karuna Therapeutics) Headlines